Elanco Animal Health (ELAN) Current Deferred Revenue (2017 - 2026)

Elanco Animal Health has disclosed Current Deferred Revenue across 10 years of filings, most recently posting $450.0 million for Q2 2026.

• In Q2 2026, Current Deferred Revenue rose 22.62% year-over-year to $450.0 million; the TTM figure through Jun 2026 stood at $450.0 million (up 22.62% YoY), while the FY2025 annual figure was $416.0 million, up 25.3% from the prior year.
• Current Deferred Revenue came in at $450.0 million for Q2 2026 at Elanco Animal Health, up from $400.0 million in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $450.0 million in Q2 2026 to a low of $284.0 million in Q2 2022.
• Average Current Deferred Revenue over 5 years is $347.8 million, with a median of $332.5 million recorded in 2023.
• Year-over-year, Current Deferred Revenue fell 10.27% in 2022 and advanced 25.39% in 2026.
• Over 5 years, Current Deferred Revenue stood at $324.0 million in 2022, then rose by 13.27% to $367.0 million in 2023, then dropped by 9.54% to $332.0 million in 2024, then rose by 25.3% to $416.0 million in 2025, then grew by 8.17% to $450.0 million in 2026.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $450.0 million in Q2 2026, $400.0 million in Q1 2026, and $416.0 million in Q4 2025.